Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

Effects of Isradipine on Induced-Parkinson’s Disease in Rats

Gholamreza Komeili 1 , * and Farzaneh Farajian-Mashhadi 2
Authors Information
1 Department of Physiology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Pharmacology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: April 30, 2016, 18 (4); e6444
  • Published Online: April 26, 2016
  • Article Type: Short Communication
  • Received: January 17, 2015
  • Accepted: November 16, 2015
  • DOI: 10.17795/zjrms-6444

To Cite: Komeili G, Farajian-Mashhadi F. Effects of Isradipine on Induced-Parkinson’s Disease in Rats, Zahedan J Res Med Sci. 2016 ; 18(4):e6444. doi: 10.17795/zjrms-6444.

Abstract
Copyright © 2016, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A. 2008; 105(2): 763-8[DOI][PubMed]
  • 2. Gorbatyuk MS, Shabashvili A, Chen W, Meyers C, Sullivan LF, Salganik M, et al. Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther. 2012; 20(7): 1327-37[DOI][PubMed]
  • 3. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience. 2011; 198: 221-31[DOI][PubMed]
  • 4. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol. 2010; 23(4): 228-42[DOI][PubMed]
  • 5. Fernandez HH. Updates in the medical management of Parkinson disease. Cleve Clin J Med. 2012; 79(1): 28-35[DOI][PubMed]
  • 6. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis. 2011; 43(2): 364-71[DOI][PubMed]
  • 7. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007; 6(10): 933-8[DOI][PubMed]
  • 8. Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol. 2012; 175(7): 627-35[DOI][PubMed]
  • 9. Ton TG, Heckbert SR, Longstreth WJ, Rossing MA, Kukull WA, Franklin GM, et al. Calcium channel blockers and beta-blockers in relation to Parkinson's disease. Parkinsonism Relat Disord. 2007; 13(3): 165-9[DOI][PubMed]
  • 10. Johnson BA, Ait-Daoud N, Wells LT. Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans. Neuropsychopharmacology. 2000; 22(5): 504-12[DOI][PubMed]
  • 11. Sautter J, Kupsch A, Earl CD, Oertel WH. Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine. Exp Brain Res. 1997; 117(1): 111-9[PubMed]
  • 12. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2007; 12
  • 13. Sarkaki A, Alavian SM, Mansouri SMT. A study on straital local electrical potential changes in animal model of parkinson`s disease. Iran J Pharm Res. 2004; 3(1): 80
  • 14. Morpurgo C. Effects of antiparkinson drugs on a phenothiazine-induced catatonic reaction. Arch Int Pharmacodyn Ther. 1962; 137: 84-90[PubMed]
  • 15. Schuster S, Doudnikoff E, Rylander D, Berthet A, Aubert I, Ittrich C, et al. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry. 2009; 65(6): 518-26[DOI][PubMed]
  • 16. Kupsch A, Gerlach M, Pupeter SC, Sautter J, Dirr A, Arnold G, et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport. 1995; 6(4): 621-5[PubMed]
  • 17. Munoz A, Carlsson T, Tronci E, Kirik D, Bjorklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol. 2009; 219(1): 298-307[DOI][PubMed]
  • 18. Tai CH, Yang YC, Pan MK, Huang CS, Kuo CC. Modulation of subthalamic T-type Ca(2+) channels remedies locomotor deficits in a rat model of Parkinson disease. J Clin Invest. 2011; 121(8): 3289-305[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments